Navigation Links
EntreMed to Present at the Bio 2007 Investor Forum
Date:10/4/2007

ROCKVILLE, Md., Oct. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Biotechnology Industry Organization 2007 Investor Forum, being held at the Palace Hotel, San Francisco, California, October 9-11, 2007. Mr. Burns' presentation is scheduled for Wednesday, October 10, 2007, at 3:15 p.m. (Pacific time) in the Telegraph Room.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director, Corporate

Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... ... is revolutionizing the way women look and feel about themselves and their sexual ... female sexual dysfunction and urinary leakage head on with a ground breaking medical ...
(Date:6/26/2017)... Antonio, TX (PRWEB) , ... June 26, 2017 ... ... physicians, their coding staff, and consumers are seeing lots of red these days. ... receive contain inaccurate charges that result from medical coding errors(1). Some studies point ...
(Date:6/26/2017)... Fitchburg, WI (PRWEB) , ... June 26, 2017 , ... ... implant consultations from Dr. Angela Cotey, with or without a referral. Dr. Cotey is ... the benefits of this preferred tooth replacement option. , Patients with missing teeth in ...
(Date:6/25/2017)... Viejo, CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music ... presets above footage and sound in the timeline and write in the lyrics to any ... before flying back out. Each line of the text can be added modularly for optimal ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at ... on Tuesday, June 13, 2017, in Rancho Palos ... and chief executive officer, is scheduled to present at 3:20 ... be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay will ... through September 13, 2017. ...
(Date:5/26/2017)... Calif. , May 25, 2017  In response ... States , Direct Relief is working with Pfizer ... Naloxone available at no cost to community health centers, ... nonprofit providers nationwide. "Pfizer has a ... to medicines and ensuring patient safety through educational activities," ...
Breaking Medicine Technology: